Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Synaffix

    - PMLiVE

    Boehringer Ingelheim and CDR-Life agree on deal worth up to $570m

    The deal focuses on T cell-based therapies for autoimmune disease

    - PMLiVE

    Boehringer’s Hernexeos granted FDA accelerated approval for lung cancer patients

    Approximately 226,650 lung cancer cases are expected to be diagnosed in the US this year

    - PMLiVE

    LEO Pharma gains access to Boehringer’s skin disease drug for €90m upfront

    Spevigo is already approved in over 40 countries to treat generalised pustular psoriasis

    - PMLiVE

    Boehringer’s Spevigo recommended by NICE for generalised pustular psoriasis

    The rare form of psoriasis can lead to serious complications such as sepsis and heart failure

    - PMLiVE

    Boehringer’s nerandomilast shows lung function benefit in phase 3 IPF and PPF trials

    The candidate is currently under review for both interstitial lung diseases in the EU and US

    - PMLiVE

    Boehringer Ingelheim and Tessellate Bio enter oncology partnership worth over €500m

    The companies will focus on developing treatments for hard-to-treat ALT-positive tumours

    - PMLiVE

    Boehringer and Cue partner to advance autoimmune disease candidate in deal worth $357m

    The B cell depletion therapy has the potential to reach patients earlier in their treatment journeys

    - PMLiVE

    Boehringer Ingelheim and Salipro Biotech enter drug development partnership

    The companies will focus on targeting proteins in areas such as cardio-renal-metabolic diseases

    - PMLiVE

    World Kidney Day – Boehringer launches CKD initiative to tackle UK health inequalities

    Approximately 10% of the UK population is affected by chronic kidney disease

    - PMLiVE

    Boehringer’s nerandomilast shows promise in phase 3 pulmonary fibrosis study

    The company said it will now be submitting a new drug application for the candidate in this indication

    - PMLiVE

    Boehringer gains access to Synaffix’s ADC technology through $1.3bn licensing deal

    The Lonza company will provide access to its ADC technologies for an undisclosed number of targets

    - PMLiVE

    GSK gains exclusive option on DualityBio’s preclinical ADC in deal worth over $1bn

    The candidate leverages DualityBio's platform against a gastrointestinal cancer target

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links